📊 LPCN Key Takeaways
Is Lipocine Inc. (LPCN) a Good Investment?
Lipocine faces severe financial distress with revenue collapsing 82.3% YoY to just $119.4K while burning $2.3M in annual operating cash flow, leaving approximately 2 years of cash runway at current burn rates. The company is deeply unprofitable with operating margins of -3224% and no visible path to sustainable profitability, despite maintaining a strong balance sheet and low debt levels.
Lipocine shows a steep revenue decline and deeply negative operating profitability, driving substantial free cash outflows. Despite low leverage and strong liquidity ratios, current cash appears insufficient relative to the burn rate, implying likely near-term financing and dilution absent a clear, durable revenue rebound.
Lipocine Inc. Key Strengths (LPCN)
- Strong balance sheet with minimal debt ($833K vs $22.8M equity)
- Excellent liquidity position (9.99x current and quick ratios) providing operational cushion
- Low financial leverage (0.04x debt/equity) reduces bankruptcy risk in near term
- Strong current and quick ratios indicate solid near-term liquidity
- Low leverage minimizes financial risk and interest burden
- Light liability load supports balance sheet flexibility
LPCN Stock Risks: Lipocine Inc. Investment Risks
- Revenue collapsed 82.3% YoY to $119.4K, indicating fundamental business disruption or loss of major revenue source
- Negative operating cash flow of $2.3M annually with only ~$5M cash remaining provides limited runway before insolvency
- Severely negative profitability metrics (-3075% net margin, -16.1% ROE) with no demonstrated operational efficiency or cost control
- Lack of revenue generation relative to operating expenses suggests company cost structure is unsustainable
- Cash burn exceeds cash on hand, creating near-term dilution/financing risk
- Revenue down 82% YoY highlights concentration and volatility risk
- Persistent negative margins and ROE indicate weak underlying unit economics
Key Metrics to Watch
- Quarterly revenue trend and identification of catalyst for 82% YoY decline
- Monthly operating cash burn rate and management actions to reduce cost structure
- Cash balance and months of runway remaining at current burn rate
- Clinical trial progress or FDA approvals for drug pipeline candidates
- Quarterly operating cash burn and months of runway
- Revenue growth and consistency (recurring vs milestone)
Lipocine Inc. (LPCN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.99x current ratio provides a solid financial cushion.
LPCN Profit Margin, ROE & Profitability Analysis
LPCN vs Healthcare Sector: How Lipocine Inc. Compares
How Lipocine Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lipocine Inc. Stock Overvalued? LPCN Valuation Analysis 2026
Based on fundamental analysis, Lipocine Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lipocine Inc. Balance Sheet: LPCN Debt, Cash & Liquidity
LPCN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lipocine Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.69 indicates the company is currently unprofitable.
LPCN Revenue Growth, EPS Growth & YoY Performance
LPCN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $93.9K | -$1.9M | $-0.35 |
| Q3 2025 | $114.6K | -$1.8M | $-0.33 |
| Q2 2025 | $89.6K | $445.0K | $0.10 |
| Q1 2025 | $93.9K | -$1.9M | $-0.35 |
| Q3 2024 | -$3.1M | -$1.8M | $-0.33 |
| Q2 2024 | $55.0K | $445.0K | $0.10 |
| Q1 2024 | $55.0K | $3.5M | $0.66 |
| Q3 2023 | -$3.1M | -$2.4M | $-0.52 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lipocine Inc. Dividends, Buybacks & Capital Allocation
LPCN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lipocine Inc. (CIK: 0001535955)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LPCN
What is the AI rating for LPCN?
Lipocine Inc. (LPCN) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LPCN's key strengths?
Claude: Strong balance sheet with minimal debt ($833K vs $22.8M equity). Excellent liquidity position (9.99x current and quick ratios) providing operational cushion. ChatGPT: Strong current and quick ratios indicate solid near-term liquidity. Low leverage minimizes financial risk and interest burden.
What are the risks of investing in LPCN?
Claude: Revenue collapsed 82.3% YoY to $119.4K, indicating fundamental business disruption or loss of major revenue source. Negative operating cash flow of $2.3M annually with only ~$5M cash remaining provides limited runway before insolvency. ChatGPT: Cash burn exceeds cash on hand, creating near-term dilution/financing risk. Revenue down 82% YoY highlights concentration and volatility risk.
What is LPCN's revenue and growth?
Lipocine Inc. reported revenue of $119.4K.
Does LPCN pay dividends?
Lipocine Inc. does not currently pay dividends.
Where can I find LPCN SEC filings?
Official SEC filings for Lipocine Inc. (CIK: 0001535955) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LPCN's EPS?
Lipocine Inc. has a diluted EPS of $-0.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LPCN's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lipocine Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LPCN stock overvalued or undervalued?
Valuation metrics for LPCN: ROE of -16.1% (sector avg: 15%), net margin of -3,075.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LPCN's AI grade for 2026?
Our dual AI analysis gives Lipocine Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LPCN's free cash flow?
Lipocine Inc.'s operating cash flow is $-2.3M, with capital expenditures of $90.1K. FCF margin is -1,965.9%.
How does LPCN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,075.4% (avg: 12%), ROE -16.1% (avg: 15%), current ratio 9.99 (avg: 2).